Our Story
Tackling twin scourges of humanity
Humanity is continuously challenged by global disease burden from AMR and cancers. Available therapies are unable to address many of these issues. We are a group of highly experienced scientists with a single focus agenda to provide novel solutions to these health threats.
New antibacterial and Next-generation cancer therapeutics are urgently needed.
Our Therapy Areas
Next-generation Oncology therapeutics
Stepping up Cancer therapeutics to the next level
Our research programs focus on discovering differentiated and affordable small molecule therapeutics for treating recalcitrant tumors.
Antibacterial Agents
Discovery of novel antibacterial agents:
Innovative solutions to combat AMR
Our solutions are products of sophisticated technologies with the potential to cover a broad range of priority pathogens in the syndromes of high unmet need, addressing many serious hospital and community infections and combating a broad spectrum of biothreat pathogens.
Project Portfolio
A key gap in the recently approved drugs, as well as those in late-stage pipeline, is the lack of oral options that cover Gram-Negative and Gram-Positive microbial infections. An intravenous and oral drug product will address the treatment of Gram-Negative and Gram-Positive infections implied in HABP/VABP, CABP, uUTI, cUTI, and other enteric infections.
Modulating the immune system through a small molecule approach offers several unique advantages that are complementary to, and potentially synergistic with, biologic modalities and are poised to significantly extend the scope of immuno-oncology applications and enhance the opportunities for combination with tumour-targeted agents and biologic immunotherapies.
Pipeline
Our pipeline consists of targeted small molecules for the treatment of multidrug-resistant microbial infections and hypoxic, immunosuppressed, refractory solid tumors.
About Us
Bugworks was set up in 2014 and incubated in C-CAMP, Bangalore. The core scientific team comes with a combined experience of over 200 years in Drug Discovery. Bugworks engages with multiple, globally reputed partners to propel its breakthrough broad-spectrum assets.
News & Announcements
Dr. Anand Anandkumar, co-founder and CEO, participated in a panel discussion on the theme “Investing in the present and securing our future together: accelerating multisectoral global, regional and national actions to address antimicrobial resistance” at the United Nations Headquarters in New York.
September 25, 2024 Published in Devex
Bugworks Research Inc. featured in The Better India for our ongoing efforts against antibiotic resistance
September 18, 2024 Published in The Better India
Bala Subramanian, co-founder and COO, presents Bugworks Research Inc.’s innovative antibiotic BWC0977 at the prestigious World AMR Congress
September 6, 2024 Published in Contagionlive
Dr. Anand Anandkumar, the co-founder and CEO of Bugworks Research Inc., was invited as a guest on an episode of the One World, One Health podcast.
August 2, 2024 Published In One Health Trust Channel
